Drug Type Small molecule drug |
Synonyms (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin, Silatecan, AR-7 + [3] |
Target |
Action inhibitors |
Mechanism TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H30N2O5Si |
InChIKeyXUSKJHCMMWAAHV-SANMLTNESA-N |
CAS Registry220913-32-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma Multiforme | Phase 2 | United States | 01 Dec 2009 | |
Glioblastoma Multiforme | Phase 2 | Canada | 01 Dec 2009 | |
Gliosarcoma | Phase 2 | United States | 01 Dec 2009 | |
Gliosarcoma | Phase 2 | Canada | 01 Dec 2009 | |
Metastatic Solid Tumor | Phase 1 | United States | 01 Oct 2006 | |
Neoplasms | Preclinical | United States | 19 Sep 2000 |
Phase 2 | 8 | qoqnuwakam(ymbnqcjoyw) = lzgkntwhaw ppkpfzhueu (ahqfatjpio ) View more | Positive | 12 Nov 2021 | |||
Placebo | qoqnuwakam(ymbnqcjoyw) = mvaotstoxj ppkpfzhueu (ahqfatjpio ) View more |